A leading metabolic health coach has announced the launch of a comprehensive evidence-based program designed to address the silent epidemic of insulin resistance affecting up to 88% of U.S. adults. The program introduces therapeutic carbohydrate restriction protocols that target pancreatic beta-cell restoration before irreversible damage occurs.

Research reveals that insulin resistance underlies nearly every chronic disease, from type 2 diabetes and heart disease to neurodegenerative conditions. Current healthcare approaches typically wait until blood glucose levels indicate prediabetes or diabetes, by which time approximately 50% of pancreatic beta-cell function may already be compromised.

"Conventional medicine focuses on managing symptoms rather than addressing root metabolic dysfunction," states the program developer. "Our approach identifies hidden hyperinsulinemia early through markers like fasting insulin levels and HOMA-IR, allowing intervention years before traditional diagnostic thresholds are reached."

The program emphasizes ultra-low carbohydrate intake combined with nutrient-dense animal proteins to reduce insulin demand and promote mitochondrial restoration. Clinical trials demonstrate that therapeutic carbohydrate restriction can achieve type 2 diabetes remission and medication discontinuation in multiple settings.

Key program components include continuous monitoring of early metabolic markers, strategic fasting protocols, and elimination of processed foods and seed oils. Participants track fasting insulin levels, triglyceride-to-HDL ratios, and waist-to-height measurements rather than relying solely on standard glucose tests.

The program addresses critical gaps in current nutritional guidelines, which have coincided with exploding rates of obesity and metabolic dysfunction. Indigenous populations historically maintained near-zero rates of these diseases until adopting modern dietary patterns high in refined carbohydrates.